[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351362-105":59,"doc-detail-351362-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-cancer-expressed-egfr-with-a-humanized-monoclonal-antibody","Targeting cancer expressed EGFR with a humanized monoclonal antibody","","Humanization of mouse monoclonal antibodies targeting tumor antigens enables safe, repeated therapeutic administration to humans. This work advances the mouse antibody 40H3, which binds a conformational EGFR epitope exposed on cancer cells, by generating multiple humanized variants and selecting the lead candidate A10. A10 shows the strongest cell-binding activity across diverse EGFR-mutant or EGFR-overexpressing cancer cell lines and is characterized structurally via A10 Fab–peptide analysis. As proof of concept, an A10-derived antibody-drug conjugate using MMAE demonstrates potent cytotoxicity against high-EGFR-expressing cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-cancer-expressed-egfr-with-a-humanized-monoclonal-antibody/351362/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-cancer-expressed-egfr-with-a-humanized-monoclonal-antibody/351362.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of humanizing the mouse monoclonal antibody 40H3?","Question",{"text":112,"@type":113},"Humanization reduces immunogenicity for humans while enabling safe repeated administration. It aims to advance 40H3 toward clinical use.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the lead humanized candidate A10 selected?",{"text":117,"@type":113},"Various humanized variants were generated and evaluated for binding to the peptide epitope and intact cells. A10 showed the strongest cell-binding activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What is demonstrated as proof of concept using A10?",{"text":121,"@type":113},"An antibody-drug conjugate (ADC) based on A10 and loaded with MMAE was created and showed potent cytotoxicity against cells with high EGFR levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351362,1790168987,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTargeting cancer expressed EGFR with a humanized monoclonal antibody  \nTamara G. Fernandes Costa1, Robert Sarnovsky1, Jingyu Zhan2, Carolyn A. Maslanka2, Ifechukwu Obiorah1, Di Xia2, David FitzGerald1 & Antonella Antignani1􀀍  \nThe humanization of mouse monoclonal antibodies targeting tumor antigens allows for the safe and repeated administration of therapeutic antibodies to humans. Previously, we reported on mouse monoclonal antibody 40H3 and its reactivity with a conformational epitope exposed on EGFR when expressed by cancer cells. To advance 40H3 toward the clinic, we generated various humanized variants, evaluated each for binding to either the peptide epitope or intact cells, and now report on the lead candidate, A10, which exhibited the strongest cell binding activity. A10 binding was characterized in detail on a collection of cancer cell lines each harboring different EGFR mutations or overexpressed EGFR and, where appropriate, compared with 40H3 or Cetuximab. A structural study of theA10 Fab with bound peptide revealed that A10 was unlikely to react with either tethered or untethered forms of wild type EGFR, as the accessibility to the peptide epitope byA10 is EGFR conformational dependent. As a proof of concept to produce therapeutic agents from A10, an antibody drug conjugate (ADC) with monomethyl-auristatin-E (MMAE) was generated and proved potently cytotoxic for cells displaying high levels of EGFR.  \nKeywords EGFR, Antibody, Tumor, Target, Antibody-antigen complex, Conformation  \nThe epidermal growth factor receptor (EGFR) has been studied intensively as a cancer target for more than four decades1,2. EGFR is an oncogenic cell surface protein, driving cancer progression via mutation or overexpression3. High affinity ligands for EGFR include EGF, TGFα, while low affinity ligands include epiregulinand epigene4. Ligand binding to the receptor’s extracellular domain (ECD) promotes dimerization and activatesan intracellular kinase domain leading to phosphorylation of a C-terminal tail rich in tyrosine residues4–6.  \nEGFR gene amplification was discovered in biopsy samples from glioblastoma (GBM) patients7. Since then, this genomic alteration has been observed in a subset of epithelial tumors including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC)8 and colorectal cancer (CRC)9, 10 resulting in EGFR overexpression. Moreover, in 50% of patient with GBM, EGFR amplification is evident in tumor samples; as is the substantial expression of EGFRvIII, a truncated variant of EGFR11, 12. EGFRvIII is a truly cancer-specific variant of EGFR where exons 2–7 are deleted and exon 1 is fused with exon 8, which is not seen in normal cells13. EGFRvIII which is constitutively active at low level as a kinase, is mostly specific for GBM and is thus a very attractive target for treating this disease.  \nBecause of its role in cancer promotion, EGFR has been the focus of therapeutics that block ligand binding or interfere with kinase-driven signaling14–17. An obvious drawback to these therapies is their collateral targeting of wildtype EGFR expressed on normal cells and tissues. An ideal targeting agent might be one with reactivity for both cancer-expressed EGFR and EGFRvIII while exhibiting little or no reactivity for wild type EGFR expressed at normal levels. In this regard, antibodies to EGFR have mainly been developed targeting overexpressed EGFR18–20 or EGFRvIII21. Previously, we published on the development of 40H3, a mouse monoclonal antibody that reacts with the 287–302 loop of EGFR on cancer cells20. This peptide is fully exposed on EGFRvIII and conformationally exposed on wild type EGFR when it is overexpressed on the surface of cancer cells19. To develop a humanized version of 40H3 with the goal of improving its utility as a clinical candidate, a total of fourteen humanized candidate antibodies were evaluated and the antibody, d","cbCaivVtnb0vwEXu","https://ap.wps.com/l/cbCaivVtnb0vwEXu","pdf",2794638,11,"English","# Targeting cancer expressed EGFR with a humanized monoclonal antibody\n## Introduction: rationale for humanizing EGFR-targeting antibodies\n## Results: Generation and evaluation of humanized variants of the 40H3 antibody","[{\"question\":\"What is the purpose of humanizing the mouse monoclonal antibody 40H3?\",\"answer\":\"Humanization reduces immunogenicity for humans while enabling safe repeated administration. It aims to advance 40H3 toward clinical use.\"},{\"question\":\"How was the lead humanized candidate A10 selected?\",\"answer\":\"Various humanized variants were generated and evaluated for binding to the peptide epitope and intact cells. A10 showed the strongest cell-binding activity.\"},{\"question\":\"What is demonstrated as proof of concept using A10?\",\"answer\":\"An antibody-drug conjugate (ADC) based on A10 and loaded with MMAE was created and showed potent cytotoxicity against cells with high EGFR levels.\"}]","Targeting cancer expressed EGFR with a humanized monoclonal antibody | PDF",1790093723,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0b4d3cea3bf88f2a4cbf5ecfa9ee731.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3217c5403dd90be5a4518e692ad22f4.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dc4872f1b1d9915c9a7eb3cc09969d2.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1d289982c9aac6672bb4832df2326ab.webp",980,1287]